Dr. David Schenkein is a general partner at GV, co-leading the life science investment team. He previously served as CEO and board member at Agios Pharmaceuticals and remains its chairman.
Kaye Foster joined the board of directors in December 2021. She has been a Senior Advisor at the Boston Consulting Group since 2014 and previously served as Senior Vice President of Global Human Resources at Onyx Pharmaceuticals, an Amgen subsidiary.
Michael A. Kelly has been on the board of directors since November 2021. He founded and leads Sentry Hill Partners, a global life sciences consulting firm, and previously held roles at other organizations from 2003 to 2017.
Robert Nelsen co-founded ARCH Venture Partners and serves as a Managing Director. He helped source, finance, and develop over 100 companies, including 27 valued at over $1 billion, and made seed investments in Illumina and Alnylam Pharmaceuticals.
